Experts discuss the ease of use and advantages to using a harmonized approach of Nuclear Magnetic Resonance and Mass Spectroscopy for the detection and identification of narcotics.
Key Topics Include:
- Increase evidence robustness by application of orthogonal methods
- Take advantage of training and maintenance synergies from one single point of contact
- Enhance ease of use and through put with harmonized methods
- Shorten time to result with benchtop instruments in every local laboratory
Head of Business Unit Industrial
Dr. Joerg Koehler studied physics and holds a doctoral degree from the Institute of Biophysics and Physical Biochemistry of the University of Regensburg. His research focused on High-Pressure-NMR based studies of folding intermediates of biochemically active macromolecules. After several positions in sales, sales management and business administration he joined Bruker as Head of Business Unit Industrial. Today Dr Joerg Koehler is accountable for Bruker’s global activities in magnetic resonance in various industrial market segments including forensics.
Product Manager FT-NMR Benchtop Solutions
Dr. Venita Decker studied Neuroscience, but did her dissertation in the field of solid-state NMR (Max Planck Institute for Biophysical Chemistry, Goettingen). In 2012, she joined the Bruker solid-state NMR application. As a NMR-late entrant she since then actively supported Bruker solutions that simplify the complexity of NMR (TopSolids, the minispec FormCheck). Since 2018, she is the Product Manager for FT-NMR benchtop solutions, bringing her mission to the next level.
Applied Solutions, Demo Team Leader & Toxtyper Specialist
Head of Bremen Applied Solutions Demo Team 1997 Post Doc, University of Braunschweig, Germany, 1996 PhD in Food Chemistry, University of Braunschweig, Germany With Bruker Daltonik since 1998, her core competences are Toxtyper and TargetScreener solutions; forensic, food, environmental and industrial applications using ion trap, QTOF and timsTOF
Additional Content From Bruker Corporation
Unlocking Your Clinical Understanding of Post-Acute COVID Syndrome (PACS), Patient Recovery, and Risk of Subsequent Disease
Watch this webinar to learn about the metabolic changes during COVID-19 disease, how these can be accurately tracked and how NMR can improve the clinical understanding of Long-COVID.
Experts provide a comprehensive overview of approaches to address cardiac and respiratory gating in PET and MRI in rodent models.
Bruker experts provide an overview of SmartDrive with a particular focus on the exciting new features. They offer practical examples and demonstrate the newest features and functions live!
Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.